2019

1. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

   The Lancet Haematology, Vol. 6, Núm. 9, pp. e448-e458